# Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study

> **NCT02454530** · — · TERMINATED · sponsor: **Pfizer** · enrollment: 1160 (actual)

## Conditions studied

- Chemotherapy-Induced Neutropenia

## Interventions

- **BIOLOGICAL:** Nivestim®

## Key facts

- **NCT ID:** NCT02454530
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2016-10-18
- **Final completion:** 2017-01
- **Target enrollment:** 1160 (ACTUAL)
- **Why stopped:** The study was stopped due to the judicial liquidation of the CRO in charge of this study.
- **Last updated:** 2019-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02454530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02454530, "Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02454530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*